Clinical Trial

A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 18, 2024 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Chemotherapy, immune checkpoint inhibitors, and anti-angiogenic targeted therapies have been explored in combination for neoadjuvant and conversion therapies. However, the efficacy of the novel anti-angiogenic agent fruquintinib in combination with immune checkpoint inhibitors and chemotherapy in the neoadjuvant and conversion treatment of locally advanced or metastatic gastric cancer has not been reported. This study aims to observe the efficacy and safety of fruquintinib combined with immune checkpoint inhibitors and chemotherapy in real-world settings.
Trial Details
NCT Number NCT06464601
Lead Sponsor Wuhan University
Conditions Gastric Cancer
Enrollment 70 participants
Start Date 2025-04-01
Primary Completion 2026-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-06-18